The Role of Direct-Acting Antivirals (DAAs) in Hepatitis C Virus-Associated Lymphoproliferative Disorders
Cancers · 04.08.2026 · 18 (15) · 2501
DOI: 10.3390/cancers18152501 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 04.08.2026. Verfasst von Cesare Mazzaro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
Hepatitis C virus (HCV) infection is a major cause of chronic hepatitis, affecting approximately 50 million people worldwide. An estimated 15–30% of individuals with chronic HCV infection progress to cirrhosis, which may subsequently develop into hepatocellular carcinoma. Beyond liver disease, HCV is associated with a broad spectrum of extrahepatic manifestations, particularly mixed cryoglobulinemia (MC) and B-cell non-Hodgkin lymphoma (B-NHL). Persistent viral infection induces chronic antigenic stimulation of B lymphocytes, a key pathogenic mechanism underlying the progression from MC to overt B-NHL. These observations have important therapeutic implications and support the use of antiviral therapy as a cornerstone of treatment. The efficacy of direct-acting antivirals (DAAs) has been well established in patients with HCV-related MC and cryoglobulinemic vasculitis. Several studies have shown that DAAs achieve sustained virologic response rates exceeding 90%, often approaching 100% in contemporary cohorts. Viral eradication is frequently associated with clinical and immunological improvement, as well as regression of cryoglobulinemia. Encouraging outcomes have also been reported in patients with HCV-associated indolent B-NHL, particularly marginal zone lymphoma, although confirmation in larger studies with longer follow-up is needed. In patients with HCV-positive aggressive lymphomas, DAAs have been safely administered in combination with immunochemotherapy, yielding promising results. This review summarizes the current evidence on HCV-associated MC and B-NHL and discusses the impact of DAA therapy on the clinical course and management of these disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
- Department of Translational Research and New Surgical and Medical Technologies, University of Pisa, 56126 Pisa, Italy.
- Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.
- Department of Internal Medicine, Hospital of Tolmezzo, 33028 Tolmezzo, Italy.
- Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
ORCID-Profile: Riccardo Bomben, Laura Gragnani, Silvia Marri, Anna Linda Zignego
Förderung
- Italian Ministry of Health
Zitieren
APA
Mazzaro, C., Bomben, R., Gragnani, L., Visentini, M., Agostinis, P., Marri, S., Zignego, A. L., & Gattei, V. (2026). The Role of Direct-Acting Antivirals (DAAs) in Hepatitis C Virus-Associated Lymphoproliferative Disorders. Cancers, 18(15), 2501. https://doi.org/10.3390/cancers18152501
Vancouver
Mazzaro C, Bomben R, Gragnani L, Visentini M, Agostinis P, Marri S, et al. The Role of Direct-Acting Antivirals (DAAs) in Hepatitis C Virus-Associated Lymphoproliferative Disorders. Cancers. 2026;18(15):2501. doi:10.3390/cancers18152501
BibTeX
@article{Mazzaro2026,
author = {Mazzaro, Cesare and Bomben, Riccardo and Gragnani, Laura and Visentini, Marcella and Agostinis, Paolo and Marri, Silvia and Zignego, Anna Linda and Gattei, Valter},
title = {The Role of Direct-Acting Antivirals (DAAs) in Hepatitis C Virus-Associated Lymphoproliferative Disorders},
journal = {Cancers},
year = {2026},
volume = {18},
number = {15},
pages = {2501},
doi = {10.3390/cancers18152501}
}
EUVIMED